Increasing cardiovascular disorders, rising geriatric population, and increasing surgical procedures support the growth of the global oral anticoagulants market in recent years. However, the high cost is likely to restrain market growth over the forecast period.
The Global Oral Anticoagulants Market is expected to grow at CAGR of 12.50% to reach USD 22,561.24 million by 2023
Anticoagulant is a drug, when added to blood, prevents it from clotting. Anticoagulants achieve their effect by suppressing the synthesis or function of various clotting factors that are normally present in the blood. Such drugs are often used to prevent the formation of blood clots (thrombi) in the veins or arteries or the enlargement of a clot that is circulating in the bloodstream.
The global oral anticoagulants market has been segmented into product, disease indication, distribution channel, and region. Based on product, the oral anticoagulants market has been segmented into novel oral anticoagulant and warfarin. On the basis of disease indication, the global oral anticoagulants market has been segmented into atrial fibrillation (AF)/ stroke prevention and deep vein thrombosis/ pulmonary embolism, and others. On the basis of distribution channel, the global oral anticoagulants market has been segmented into hospital pharmacies, retail pharmacies, and E-commerce.
This research report provides the insights, on various levels of analyses such as industry analysis, market share analysis leading market players and their profiles. This report also helps in studying the target segments by providing views on emerging & high-growth segments and market conclusion.
Together the market data comprise and discuss with the basic assessments on the competitive scenarios & strategies, of the Global Oral Anticoagulants Market, including the high-growth regions and their political, economic and technological environments. Furthermore, the project report also provides the views over the historical market values as well as, pricing and cost analysis of the same.